Utilizing Targeted Enhanced-Whole-Genome Sequencing in Precision Oncology for the Treatment of Solid Tumors: A Clinical Perspective
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background Genomic alterations in tumors provide key insights into the clinical management of patients. Over the past decade, targeted panel sequencing (TPS) has been a key tool in oncology. With recent advances in sequencing technology and cost reduction, whole-genome sequencing (WGS) has now become a viable and comprehensive method for analyzing cancer genomes. Methods A retrospective analysis of 24 cases to evaluate the clinical utility of targeted enhanced whole-genome sequencing (TE-WGS). The TE-WGS assay was evaluated by assessing its impact on targeted therapy selection, clinical trial opportunities, exclusion of non-beneficial therapies, and diagnostic clarity. Results TE-WGS demonstrated clinical utility in 71% of cases. 50% of cases reveal actionable genomic alterations aligned to on- and off-label targeted therapies. Notably, 50% of patients exhibited genomic profiles that aligned with ongoing clinical trials. Conclusion This report underscores the clinical value of TE-WGS in providing a nuanced genomic landscape that can be integrated into clinical practice for precision oncology, thereby enhancing personalized treatment strategies.
